Raymond James & Associates Has $133.24 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Raymond James & Associates lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 6.9% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 318,757 shares of the pharmaceutical company’s stock after selling 23,660 shares during the period. Raymond James & Associates owned approximately […]

Related Keywords

Ourania Tatsis ,Chevy Chase Trust Holdings ,News Ratings For Vertex Pharmaceuticals Daily ,Vertex Pharmaceuticals Trading Down ,Canaccord Genuity Group ,Barclays ,Quarter For Vertex Pharmaceuticals ,Vertex Pharmaceuticals ,Vertex Pharmaceuticals Profile ,Raymond James Associates ,Jpmorgan Chase Co ,Vertex Pharmaceuticals Incorporated ,Securities Exchange Commission ,Atlantic Union Bankshares Corp ,Raymond James ,Free Report ,Union Bankshares Corp ,Capital Management ,Pacific Financial ,Chase Trust Holdings ,Exchange Commission ,Chairman Jeffrey ,Genuity Group ,Pharmaceuticals Trading Down ,Pharmaceuticals Incorporated ,Get Free Report ,Vertex Pharmaceuticals Daily ,Nasdaq Vrtx ,Vrtx ,Medical ,92532f10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,